Slideshow

Real-World Effectiveness of Antipsychotics

Author(s):

Brian Miller, MD, PhD, MPH

Which of these agents best prevents relapse? A recent study employed a novel approach to find out.

Related Videos
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
nicotine use
brain schizophrenia
schizophrenia
schizophrenia
exciting, brain
Related Content
research
October 11th 2024

Uzedy: Reducing the Risk of Relapse in Patients With Schizophrenia

Christoph U. Correll, MD
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
clozapine
October 3rd 2024

Clozapine REMS: Regulatory Discrimination Against Psychiatrists?

Gilbert Honigfeld, PhD
Treating ‘Morally Objectionable’ Patients
September 27th 2021

Treating ‘Morally Objectionable’ Patients

James L. Knoll IV, MD
brain research
October 2nd 2024

Cobenfy: The Tip of the Spear of A New Class of Antipsychotics

John H. Krystal, MD
schizophrenia
October 1st 2024

The FDA Approval of Cobenfy: A Historic Moment in Schizophrenia

John H. Krystal, MD
© 2024 MJH Life Sciences

All rights reserved.